403 related articles for article (PubMed ID: 28867283)
1. Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression.
Meier TB; Drevets WC; Teague TK; Wurfel BE; Mueller SC; Bodurka J; Dantzer R; Savitz J
Brain Behav Immun; 2018 Jan; 67():59-64. PubMed ID: 28867283
[TBL] [Abstract][Full Text] [Related]
2. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
[TBL] [Abstract][Full Text] [Related]
3. Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.
Young KD; Drevets WC; Dantzer R; Teague TK; Bodurka J; Savitz J
Brain Behav Immun; 2016 Aug; 56():335-42. PubMed ID: 27091600
[TBL] [Abstract][Full Text] [Related]
4. C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder.
Zheng H; Teague TK; Yeh FC; Burrows K; Figueroa-Hall LK; Aupperle RL; Khalsa SS; Paulus MP; Savitz J
Brain Behav Immun; 2022 Oct; 105():180-189. PubMed ID: 35853557
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.
Savitz J; Dantzer R; Wurfel BE; Victor TA; Ford BN; Bodurka J; Bellgowan PS; Teague TK; Drevets WC
Psychoneuroendocrinology; 2015 Feb; 52():200-11. PubMed ID: 25486577
[TBL] [Abstract][Full Text] [Related]
6. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.
Savitz J; Drevets WC; Wurfel BE; Ford BN; Bellgowan PS; Victor TA; Bodurka J; Teague TK; Dantzer R
Brain Behav Immun; 2015 May; 46():55-9. PubMed ID: 25686798
[TBL] [Abstract][Full Text] [Related]
7. Sleep disturbance and kynurenine metabolism in depression.
Cho HJ; Savitz J; Dantzer R; Teague TK; Drevets WC; Irwin MR
J Psychosom Res; 2017 Aug; 99():1-7. PubMed ID: 28712413
[TBL] [Abstract][Full Text] [Related]
8. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
[TBL] [Abstract][Full Text] [Related]
9. Serum kynurenic acid is reduced in affective psychosis.
Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
[TBL] [Abstract][Full Text] [Related]
10. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.
Savitz J; Drevets WC; Smith CM; Victor TA; Wurfel BE; Bellgowan PS; Bodurka J; Teague TK; Dantzer R
Neuropsychopharmacology; 2015 Jan; 40(2):463-71. PubMed ID: 25074636
[TBL] [Abstract][Full Text] [Related]
11. Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder.
Savitz J; Dantzer R; Meier TB; Wurfel BE; Victor TA; McIntosh SA; Ford BN; Morris HM; Bodurka J; Teague TK; Drevets WC
Psychoneuroendocrinology; 2015 Dec; 62():54-8. PubMed ID: 26232650
[TBL] [Abstract][Full Text] [Related]
12. Real-time fMRI neurofeedback amygdala training may influence kynurenine pathway metabolism in major depressive disorder.
Tsuchiyagaito A; Smith JL; El-Sabbagh N; Zotev V; Misaki M; Al Zoubi O; Kent Teague T; Paulus MP; Bodurka J; Savitz J
Neuroimage Clin; 2021; 29():102559. PubMed ID: 33516062
[TBL] [Abstract][Full Text] [Related]
13. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
Birner A; Platzer M; Bengesser SA; Dalkner N; Fellendorf FT; Queissner R; Pilz R; Rauch P; Maget A; Hamm C; Herzog-Eberhard S; Mangge H; Fuchs D; Moll N; Zelzer S; Schütze G; Schwarz M; Reininghaus B; Kapfhammer HP; Reininghaus EZ
PLoS One; 2017; 12(2):e0172699. PubMed ID: 28241062
[TBL] [Abstract][Full Text] [Related]
14. A mood state-specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder.
van den Ameele S; van Nuijs AL; Lai FY; Schuermans J; Verkerk R; van Diermen L; Coppens V; Fransen E; de Boer P; Timmers M; Sabbe B; Morrens M
Bipolar Disord; 2020 Feb; 22(1):59-69. PubMed ID: 31398273
[TBL] [Abstract][Full Text] [Related]
15. The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis.
Ou W; Chen Y; Ju Y; Ma M; Qin Y; Bi Y; Liao M; Liu B; Liu J; Zhang Y; Li L
J Affect Disord; 2023 Oct; 339():624-632. PubMed ID: 37467793
[TBL] [Abstract][Full Text] [Related]
16. Peripheral and central levels of kynurenic acid in bipolar disorder subjects and healthy controls.
Sellgren CM; Gracias J; Jungholm O; Perlis RH; Engberg G; Schwieler L; Landen M; Erhardt S
Transl Psychiatry; 2019 Jan; 9(1):37. PubMed ID: 30696814
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
Brain Behav Immun; 2018 Nov; 74():205-212. PubMed ID: 30213652
[TBL] [Abstract][Full Text] [Related]
18. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Ning Y
Psychoneuroendocrinology; 2019 Mar; 101():72-79. PubMed ID: 30419374
[TBL] [Abstract][Full Text] [Related]
19. Acute administration of ibuprofen increases serum concentration of the neuroprotective kynurenine pathway metabolite, kynurenic acid: a pilot randomized, placebo-controlled, crossover study.
Savitz J; Ford BN; Kuplicki R; Khalsa S; Teague TK; Paulus MP
Psychopharmacology (Berl); 2022 Dec; 239(12):3919-3927. PubMed ID: 36271950
[TBL] [Abstract][Full Text] [Related]
20. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.
Sun Y; Drevets W; Turecki G; Li QS
Brain Behav Immun; 2020 Jul; 87():404-412. PubMed ID: 31978524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
